公开(公告)号：US20230072867A1

公开(公告)日：2023-03-09

申请号：US17730463

申请日：2022-04-27

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20220356166A1

公开(公告)日：2022-11-10

申请号：US17168574

申请日：2021-02-05

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US11370774B2

公开(公告)日：2022-06-28

申请号：US17202965

申请日：2021-03-16

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20210221786A1

公开(公告)日：2021-07-22

申请号：US17202965

申请日：2021-03-16

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US12043610B2

公开(公告)日：2024-07-23

申请号：US17730463

申请日：2022-04-27

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20240239752A1

公开(公告)日：2024-07-18

申请号：US18286615

申请日：2022-04-14

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Zhao Dang ,  Krishnan Raman

IPC: C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.

公开(公告)号：US20230303611A1

公开(公告)日：2023-09-28

申请号：US18100192

申请日：2023-01-23

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Zhao Dang ,  Minwan Wu

IPC: C07H19/14 ,  C07H1/04

CPC classification number: C07H19/14 ,  C07H1/04

Abstract: Provided are methods of making the active 5′-triphosphate form of galidesivir (compound 1) and the active 5′-triphosphate form of azasugar nucleoside analogues (compound 2):










a potent anti-viral compound useful for broad spectrum treatment, suppression, and prevention of viral infections. The syntheses of compound 1 and compound 2 can be achieved via selective formation of protected intermediate 1b and protected intermediate 2b, respectively:

公开(公告)号：US20240294494A1

公开(公告)日：2024-09-05

申请号：US18407053

申请日：2024-01-08

Applicant: BioCryst Pharmaceuticals, Inc

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20230099716A1

公开(公告)日：2023-03-30

申请号：US17730438

申请日：2022-04-27

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US11021458B2

公开(公告)日：2021-06-01

申请号：US16511642

申请日：2019-07-15

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.